Is Agenus Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Agenus Inc (AGEN) is currently classified as DOUBTFUL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Agenus Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Agenus Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Agenus Inc?

Muslim investors may consider investing in Agenus Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Agenus Inc classified as DOUBTFUL?

Musaffa determines the Shariah status of Agenus Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Agenus Inc updated?

The Shariah compliance status of Agenus Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Agenus Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Agenus Inc?

You can check the latest Shariah compliance status of Agenus Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

AGEN Shariah Compliance

Screening Methodology: AAOIFI

DOUBTFUL

Last Updated: March 17, 2026

Report Source: 2025 Annual Report

Agenus Inc. Stock Analysis AGEN

United States Health Care Micro Cap Report: 2025 Annual

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2000-02-04. The firm is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The firm has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Key Statistics of Agenus Inc (AGEN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$3.42$3.60

Today's Open

$3.52

Volume

511.89K

P/E Ratio (TTM)

1,296.35

52 Week Range

$2.71$7.34

Market Cap

160.12M

Avg. Volume

931.06K

Dividend Yield

Financial Metrics & Statements of Agenus Inc (AGEN)

FAQ's for Agenus Inc (AGEN)

According to Musaffa’s Shariah screening methodology, Agenus Inc (AGEN) is currently classified as DOUBTFUL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.